Miravirsen (Santaris Pharma) Phase II trial for Hepatitis C is reported in NEJM

Santaris Pharma A/S, has announced the publication of study results online in the New England Journal of Medicine (NEJM). The publication highlights the potential benefits of miravirsen, a host-targeted, pan-HCV genotype anti-viral agent and the first microRNA-targeted drug to enter clinical trials for the treatment of Hepatitis C virus (HCV). In the study, miravirsen, given as a four-week monotherapy treatment, provided robust dose- dependent antiviral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL). The effect was sustained well beyond the end of therapy.

see "Treatment of HCV Infection by Targeting MicroRNA"- Harry L.A. Janssen, M.D., Ph.D., Hendrik W. Reesink, M.D., Ph.D., Eric J. Lawitz, M.D., et al -March 27, 2013DOI: 10.1056/NEJMoa1209026